Naproxen: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), HAS (France) and SMC (Scotland) recommended or restricted naproxen, while PHARMAC (New Zealand) did not recommend it.
CONITEC (Brazil) has been easier on naproxen than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 44% across everything it has assessed.
The file has been open for more than a decade: 14.8 years separate the first record, 21 Jul 2010 at HAS (France), from the most recent, 9 Apr 2025 at HAS (France).
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 2 of 16 records date from 2023 or later.
HAS (France) was first to assess naproxen, on 21 Jul 2010; SMC (Scotland) did not open a file until 13 Jun 2016 — a wide spread of 5.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 10 years in total.
3 of the 5 agencies here assessed naproxen more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed naproxen.
The full ledger for naproxen reads 10 recommended, 2 other, 1 advice and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 9 Apr 2025 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| PHARMAC (New Zealand) | 7 Nov 2023 | Inflammation and pain | funding application decided · decision reached | source |
| CONITEC (Brazil) | 13 Nov 2020 | Tratamento de pacientes com artrite reativa | incorporated into SUS | source |
| SMC (Scotland) | 13 Jun 2016 | treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults. | accepted (restricted) | source |
| AWMSG (Wales) | 26 Jan 2016 | Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoe… | outside AWMSG criteria | source |
11 further decisions for naproxen, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- fezolinetant — same ATC class G02C — Other gynecologicals
- osimertinib — also decided by HAS in 2025Q2
- ofatumumab — also decided by HAS in 2025Q2
- efgartigimod alfa — also decided by HAS in 2025Q2
- risdiplam — also decided by HAS in 2025Q2
- pitolisant — also decided by HAS in 2025Q2
Coverage: 16 decisions for naproxen from 5 agencies, 2010 to 2025. Data to 7 Sep 2026. ATC class G02C — Other gynecologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.